Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI8968 in moderate to severe hidradenitis suppurativa
NCT01838499Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- May 2013
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of AMG 108 in hidradenitis suppurativa (HS), sponsored by AstraZeneca. Started May 2013; status: terminated.
02
Drugs
AMG 108
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT01838499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01838499.